NASDAQ:XBIT - XBiotech Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.81
▲ +0.43 (2.63%)

This chart shows the closing price for XBIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New XBiotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XBIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XBIT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for XBiotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $16.81.

This chart shows the closing price for XBIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in XBiotech. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2020Piper SandlerLower Price TargetOverweight$28.00 ➝ $18.00Low
12/11/2019Piper Jaffray CompaniesBoost Price TargetOverweight$16.00 ➝ $28.00Low
11/13/2019Piper Jaffray CompaniesReiterated RatingOverweight$13.00 ➝ $16.00High
6/14/2019Piper Jaffray CompaniesInitiated CoverageOverweight$13.00Low
6/3/2017Stifel NicolausUpgradeHold ➝ BuyHigh
4/21/2017Noble FinancialReiterated RatingBuy ➝ Hold$13.00High
6/28/2016Noble FinancialReiterated RatingBuy$24.00 ➝ $30.00N/A
(Data available from 6/24/2016 forward)
XBiotech logo
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $16.81
Low: $16.25
High: $16.85

50 Day Range

MA: $16.99
Low: $15.83
High: $17.84

52 Week Range

Now: $16.81
Low: $13.69
High: $21.48

Volume

61,878 shs

Average Volume

88,311 shs

Market Capitalization

$504.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of XBiotech?

The following Wall Street analysts have issued stock ratings on XBiotech in the last twelve months:
View the latest analyst ratings for XBIT.

What is the current price target for XBiotech?

0 Wall Street analysts have set twelve-month price targets for XBiotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for XBiotech in the next year.
View the latest price targets for XBIT.

What is the current consensus analyst rating for XBiotech?

XBiotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for XBIT.

What other companies compete with XBiotech?

How do I contact XBiotech's investor relations team?

XBiotech's physical mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company's listed phone number is 512-386-2900 and its investor relations email address is [email protected] The official website for XBiotech is www.xbiotech.com.